Larka’s Lensource® solution supported 4 undisclosed Biotech & Pharma companies with the selection of their Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) partners in September 2023.
![](/en/news/resources/image/65362c54e411dbody_sept_23.png)
We are delighted to announce that Larka has successfully performed 4 sourcing processes in September 2023, supporting our clients’ programs all along the value chain—i.e. preclinical, early and late clinical, and commercial supply.
Developed by Larka, Lensource® is a proprietary sourcing process which includes 360° suppliers scanning and RFI | RFQ comparison matrixes.
Leveraging Lensource®, Larka enabled the identification and selection of CRO, CDMO and CMO partners for 4 major Biotech & Pharma clients, including:
- A German-based Pharma company looking for a Drug Product (DP) CDMO partner—for the commercial supply of a Highly Potent API requiring aseptic filling into 10mL vials.
- A Swiss-based Biopharmaceutical company looking for a DP CMO partner—for the commercial supply of a parenteral product currently in Phase 3.
- A US-based Biotech company looking for a CRO partner—for the generation and lead optimization of bi-specific antibodies.
- A Swiss-based Pharma company looking for a DP CDMO partner—for DP formulation & analytical methods development, and Final DP manufacturing for Phase 1 clinical supply.
The ever-growing success of Lensource® is something we take pride in. Such accomplishments underscore our relentless commitment to building best-in-class sourcing solutions and reinforce Larka’s position as a preferred partner within Pharma.
Maxime Clarhaut | Senior Associate at Larka
Why they chose Larka
Since 1993, over 500 Biotech and Pharma companies have trusted our broad biopharma sourcing capabilities and strong track record, which include:
- 100+ CRO, CDMO, CMO and CTS sourcing projects for BioPharma companies each year
- 2000+ Contract Service Providers (CSP) monitored daily via Lensource®
- Full Coverage of value chain, CSP typologies and drug modalities
- 500Mn industry data collected, processed and analysed each year
How we supported our clients
Larka provided its clients with the full Lensource® solution, supporting the identification and selection of their future partners.
Lensource® is a 3-phase proprietary methodology combining the unique expertise of our specialists with advanced AI technologies—designed to provide our clients with actionable insights at a faster pace and deeper level.
Phase I - Market Scanning
360° screening & identification based on client's primary search criteria, offering a complete view of all the potential partners available.
Phase II - Capabilities Assessment | RFI
Thorough technical capabilities assessment and CDA process management—leading to the generation of our Lensource® matrix, developed for optimal technical data collection, standardization and comparability.
Phase III - Quotations Assessment | RFQ
Proposals and Quotations gathering and analysis—leading to the generation of our Lensource® matrix, developed for optimal pricing collection, standardization and comparability.